Nicolas Wolff

Dr. Nicolas Wolff


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2012 in Science Signaling
Verified
Journal Article
Closed access
PDF file
ETElouan Terrien
Elouan Terrien
ACAlain Chaffotte
Alain Chaffotte
MLMireille Lafage
Mireille Lafage
ZKZakir Khan
Zakir Khan
CPChristophe Préhaud
Christophe Préhaud
NWNicolas Wolff
Nicolas Wolff
The G protein of rabies virus manipulates the cellular localization of PTEN, which may promote cell survival.

17 April 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
CCCélia Caillet-Saguy
Célia Caillet-Saguy
FDFabien Durbesson
Fabien Durbesson
VRVeronica V. Rezelj
Veronica V. Rezelj
GGGergö Gogl
Gergö Gogl
QTQuang Dinh Tran
Quang Dinh Tran
NWNicolas Wolff
Nicolas Wolff
Small linear motifs targeting protein interacting domains called PSD‐95/Dlg/ZO‐1 (PDZ) have been identified at the C terminus of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) proteins E, 3a, and N. Using a high‐throughput approach of affinity‐profiling against the full human PDZome, we identified sixteen human PDZ binders of SARS‐CoV‐2 proteins E, 3A, and N showing significant interactions with dissociation constants values ranging from 3 to 82 μm. Six of them (TJP1, PTPN13, HTRA1, PARD3, MLLT4, LNX2) are also recognized by SARS‐CoV while three (NHERF1, MAST2, RADIL) are specific to SARS‐CoV‐2 E protein. Most of these SARS‐CoV‐2 protein partners are involved in cellular junctions/polarity and could be also linked to evasion mechanisms of the immune responses during viral infection. Among the binders of the SARS‐CoV‐2 proteins E, 3a, or N, seven significantly affect viral replication under knock down gene expression in infected cells. This PDZ profiling identifying human proteins potentially targeted by SARS‐CoV‐2 can help to understand the multifactorial severity of COVID19 and to conceive effective anti‐coronaviral agents for therapeutic purposes.

23 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SBSophie Boucher
Sophie Boucher
FTFabienne Wong Jun Tai
Fabienne Wong Jun Tai
SDSedigheh Delmaghani
Sedigheh Delmaghani
ALAndrea Lelli
Andrea Lelli
ASAmrit Singh-Estivalet
Amrit Singh-Estivalet
CPChristine Petit
Christine Petit
Presbycusis, or age-related hearing loss (ARHL), is a major public health issue. About half the phenotypic variance has been attributed to genetic factors. Here, we assessed the contribution to presbycusis of ultrarare pathogenic variants, considered indicative of Mendelian forms. We focused on severe presbycusis without environmental or comorbidity risk factors and studied multiplex family age-related hearing loss (mARHL) and simplex/sporadic age-related hearing loss (sARHL) cases and controls with normal hearing by whole-exome sequencing. Ultrarare variants (allele frequency [AF] < 0.0001) of 35 genes responsible for autosomal dominant early-onset forms of deafness, predicted to be pathogenic, were detected in 25.7% of mARHL and 22.7% of sARHL cases vs. 7.5% of controls (P = 0.001); half were previously unknown (AF < 0.000002). MYO6, MYO7A, PTPRQ, and TECTA variants were present in 8.9% of ARHL cases but less than 1% of controls. Evidence for a causal role of variants in presbycusis was provided by pathogenicity prediction programs, documented haploinsufficiency, three-dimensional structure/function analyses, cell biology experiments, and reported early effects. We also established Tmc1N321I/+ mice, carrying the TMC1:p.(Asn327Ile) variant detected in an mARHL case, as a mouse model for a monogenic form of presbycusis. Deafness gene variants can thus result in a continuum of auditory phenotypes. Our findings demonstrate that the genetics of presbycusis is shaped by not only well-studied polygenic risk factors of small effect size revealed by common variants but also, ultrarare variants likely resulting in monogenic forms, thereby paving the way for treatment with emerging inner ear gene therapy. Significance Presbycusis, or age-related hearing loss, is a major public health issue and the principal potentially modifiable risk factor for dementia. It is caused by environmental factors and largely uncharacterized genetic factors. We compared DNA sequences across genomic coding regions between familial or sporadic cases of severe presbycusis and controls with normal hearing. The frequency of ultrarare predicted pathogenic variants in genes known to cause dominant early-onset forms of deafness was significantly higher in both familial and sporadic cases than in controls. Pathogenicity of many of these variants was established with complementary analyses. Ultrarare variants have a large effect size and are known to cause monogenic disorders. These findings open up possibilities for curing these forms of presbycusis by gene therapy.

1 October 2015 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
CCCélia Caillet-Saguy
Célia Caillet-Saguy
PMPierre Maisonneuve
Pierre Maisonneuve
FDFlorent Delhommel
Florent Delhommel
ETElouan Terrien
Elouan Terrien
NBNicolas Babault
Nicolas Babault
NWNicolas Wolff
Nicolas Wolff

1 August 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PMPierre Maisonneuve
Pierre Maisonneuve
CCCélia Caillet-Saguy
Célia Caillet-Saguy
MVMarie-Christine Vaney
Marie-Christine Vaney
EBEdoo Bibi-Zainab
Edoo Bibi-Zainab
KSKristi Sawyer
Kristi Sawyer
NWNicolas Wolff
Nicolas Wolff
The human protein tyrosine phosphatase non-receptor type 4 (PTPN4) prevents cell death induction in neuroblastoma and glioblastoma cell lines in a PDZ·PDZ binding motifs-dependent manner, but the cellular partners of PTPN4 involved in cell protection are unknown. Here, we described the mitogen-activated protein kinase p38γ as a cellular partner of PTPN4. The main contribution to the p38γ·PTPN4 complex formation is the tight interaction between the C terminus of p38γ and the PDZ domain of PTPN4. We solved the crystal structure of the PDZ domain of PTPN4 bound to the p38γ C terminus. We identified the molecular basis of recognition of the C-terminal sequence of p38γ that displays the highest affinity among all endogenous partners of PTPN4. We showed that the p38γ C terminus is also an efficient inducer of cell death after its intracellular delivery. In addition to recruiting the kinase, the binding of the C-terminal sequence of p38γ to PTPN4 abolishes the catalytic autoinhibition of PTPN4 and thus activates the phosphatase, which can efficiently dephosphorylate the activation loop of p38γ. We presume that the p38γ·PTPN4 interaction promotes cellular signaling, preventing cell death induction.

27 August 2014 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
PMPierre Maisonneuve
Pierre Maisonneuve
CCCélia Caillet‐Saguy
Célia Caillet‐Saguy
BRBertrand Raynal
Bertrand Raynal
BGBernard Gilquin
Bernard Gilquin
ACAlain Chaffotte
Alain Chaffotte
NWNicolas Wolff
Nicolas Wolff
The human protein tyrosine phosphatase non‐receptor type 4 (PTPN4) prevents cells death. Targeting its PDZ domain abrogates this protection and triggers apoptosis. We demonstrate here that the PDZ domain inhibits the phosphatase activity of PTPN4. The mere binding of a PDZ ligand is sufficient to release the catalytic inhibition. We combined analytical ultracentrifugation, small angle X‐ray scattering and NMR to understand how the PDZ domain controls PTPN4 activity. We show that the physiologically active PTPN4 two‐domain, encompassing the PDZ and the phosphatase domains, adopts a predominant compact conformation in solution. The PDZ ligand binding restores the catalytic competence of PTPN4 disrupting the transient interdomain communication. This study strengthens the emerging notion that PDZ domains can act as regulators of enzyme activity and therefore are active players in the dynamic regulation of signaling pathways.Structured digital PTPN4_linker-PTP dephosphorylates pTyr peptide by enzymatic study (View interaction) PTPN4_PDZ-PTP dephosphorylates pTyr peptide by enzymatic study (View interaction)